INBX

$111.42-2.55%

Inhibrx Biosciences, Inc.

Market Cap

$1.7B

Sector

Materials

Industry

Biotechnology

Beta

3.80

5yr monthly vs SPY

Price Chart

Loading…

Signals

Insider Velocity

Market & Alt Data

News

9

recent articles

Analyst Consensus

Strong Buy

10 analysts

Buy Activity

Buy Velocity Score

25.65x

Current Rate (90d)

361.11/mo

Baseline Rate

0.00/mo

Unique Buyers (90d)

3

Sell Activity

Sell Velocity Score

23.98x

Sell Rate (90d)

11.11/mo

Sell Baseline

0.00/mo

Unique Sellers (90d)

1

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-09-09	2026-09-10	MANHARD KIMBERLY	Director	Sale	500	$115.80	$58K	9,000	View
2026-09-08	2026-09-10	MANHARD KIMBERLY	Director	Sale	500	$115.14	$58K	9,500	View
2026-09-08	2026-09-08	Lappe Mark	Director & Chief Executive Officer	Purchase	25.0K	$105.82	$2.65M	730.5K	View
2026-09-08	2026-09-08	FORSYTH DOUGLAS	Director	Purchase	2,500	$114.65	$287K	227.1K	View
2026-09-08	2026-09-08	Kayyem Jon Faiz	Director	Purchase	5,000	$113.52	$568K	424.4K	View

Recent News

Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data

Yahoo Finance · 2026-09-08

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study

Yahoo Finance · 2026-09-08

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study

Yahoo Finance · 2026-09-04

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

Yahoo Finance · 2026-06-15

Informational purposes only, not investment advice.